{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T22:58:07Z","timestamp":1788562687231,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T00:00:00Z","timestamp":1578528000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T00:00:00Z","timestamp":1578528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["High Blood Press Cardiovasc Prev"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s40292-020-00358-1","type":"journal-article","created":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T06:58:11Z","timestamp":1578553091000},"page":"43-49","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease"],"prefix":"10.1007","volume":"27","author":[{"given":"Francesco","family":"Fici","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Ari Bakir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Ilkay Y\u00fcce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serdal","family":"Kanuncu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Makel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahar Arican","family":"Tarim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4984-6691","authenticated-orcid":false,"given":"Nicol\u00e1s Roberto","family":"Robles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,9]]},"reference":[{"key":"358_CR1","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"MF Piepoli","year":"2016","unstructured":"Piepoli MF, Arno WH, Agewal S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37:2315\u201381.","journal-title":"Eur Heart J"},{"key":"358_CR2","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","volume":"382","author":"RT Gansevoort","year":"2013","unstructured":"Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms and prevention. Lancet. 2013;382:339\u201352.","journal-title":"Lancet"},{"key":"358_CR3","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.kint.2016.09.037","volume":"91","author":"JJ Carrero","year":"2017","unstructured":"Carrero JJ, Grams ME, Sang Y, et al. Albuminuria changes are associated with subsequent risk of end-stage renal disease and mortality. Kidney Int. 2017;91:244\u201351.","journal-title":"Kidney Int"},{"key":"358_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/ki.2010.531","volume":"80","author":"RT Gansevoort","year":"2011","unstructured":"Gansevoort RT, Matsushita K, van der Velde M, et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes: a collaborative meta-analysis of general and high-risk population cohorts. Kidney Int. 2011;80:93\u2013104.","journal-title":"Kidney Int"},{"key":"358_CR5","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.2337\/db06-1646","volume":"56","author":"S Araki","year":"2007","unstructured":"Araki S, Haneda M, Koya D, et al. Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes. Diabetes. 2007;56:1727\u201330.","journal-title":"Diabetes"},{"key":"358_CR6","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1681\/ASN.2014070688","volume":"26","author":"HJ Heerspink","year":"2015","unstructured":"Heerspink HJ, Kr\u00f6pelin TF, Hoekman J, et al. Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis. J Am Soc Nephrol. 2015;26:2055\u201364.","journal-title":"J Am Soc Nephrol"},{"key":"358_CR7","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1\u2013150."},{"issue":"39","key":"358_CR8","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"2018","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, et al. ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;2018(39):3021\u2013104.","journal-title":"Eur Heart J"},{"key":"358_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pmed.1001971","volume":"13","author":"F Catal\u00e1-L\u00f3pez","year":"2016","unstructured":"Catal\u00e1-L\u00f3pez F, Mac\u00edas Saint-Gerons D, Gonz\u00e1lez-Bermejo D, et al. Cardiovascular and renal outcomes of renin-angiotensin system blockade in adult patients with diabetes mellitus: a systematic review with network meta-analyses. PLoS Med. 2016;13:1\u201330.","journal-title":"PLoS Med"},{"key":"358_CR10","unstructured":"National Institute for Health and Care Excellence\u2014(NICE) Chronic Kidney Disease. 2014, pp. 1\u2013444."},{"key":"358_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjdrc-2015-000154","volume":"4","author":"B Wu","year":"2016","unstructured":"Wu B, Bell K, Stanford A, et al. Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns-NHANES 2007\u20132012. BMJ Open Diabetes Res Care. 2016;4:1\u201311.","journal-title":"BMJ Open Diabetes Res Care."},{"key":"358_CR12","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.amjmed.2008.09.038","volume":"122","author":"DS Wald","year":"2009","unstructured":"Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122:290\u2013300.","journal-title":"Am J Med"},{"key":"358_CR13","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC8). JAMA. 2014;311:507\u201320.","journal-title":"JAMA"},{"key":"358_CR14","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","volume":"34","author":"L Ryden","year":"2013","unstructured":"Ryden L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2013;34:3035\u201387.","journal-title":"Eur Heart J"},{"key":"358_CR15","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.pcd.2018.08.008","volume":"12","author":"F Fici","year":"2018","unstructured":"Fici F, Bakir EA, Beyazc S, et al. PAIT-survey\u2014prevalence of albuminuria in patients with diabetes and hypertension in Turkey. Primary Care Diabetes. 2018;12:558\u201364.","journal-title":"Primary Care Diabetes."},{"key":"358_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.amjmed.2015.08.025","volume":"129","author":"JA Vassalotti","year":"2016","unstructured":"Vassalotti JA, Centor R, Turner BJ. Practical approach to detection and management of chronic kidney disease for the primary care clinician. Am J Med. 2016;129:153\u201362.","journal-title":"Am J Med"},{"key":"358_CR17","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1001\/jama.2015.0602","volume":"313","author":"AS Levey","year":"2015","unstructured":"Levey AS, Becker C, Inker LA, et al. Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. JAMA. 2015;313:837\u201346.","journal-title":"JAMA"},{"key":"358_CR18","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.2337\/dc17-S001","volume":"40","author":"American Diabetes Association","year":"2017","unstructured":"American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2017;40:S1\u2013135.","journal-title":"Diabetes Care"},{"issue":"34","key":"358_CR19","first-page":"2159","volume":"2013","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K, et al. ESH\/ESC guidelines for the management of arterial hypertension. Eur Heart J. 2013;2013(34):2159\u2013219.","journal-title":"Eur Heart J"},{"key":"358_CR20","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.2215\/CJN.02850315","volume":"10","author":"DJ Leehey","year":"2015","unstructured":"Leehey DJ, Zhang JH. Emanuele NV BP and renal outcomes in diabetic kidney disease: the veterans affairs nephropathy in diabetes trial. Clin J Am Soc Nephrol. 2015;10:2159\u201369.","journal-title":"Clin J Am Soc Nephrol"},{"key":"358_CR21","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","volume":"67","author":"X Xie","year":"2016","unstructured":"Xie X, Liu Y, Perkovic V, et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis. 2016;67:728\u201341.","journal-title":"Am J Kidney Dis"},{"key":"358_CR22","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1097\/HJH.0000000000001276","volume":"35","author":"C Thomopoulos","year":"2017","unstructured":"Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trial. J Hypertens. 2017;35:922\u201344.","journal-title":"J Hypertens"},{"key":"358_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmj.f6008","volume":"347","author":"HY Wu","year":"2013","unstructured":"Wu HY, Huang JW, Lin HJ, et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. BMJ. 2013;347:1\u201315.","journal-title":"BMJ."},{"key":"358_CR24","first-page":"1","volume":"12","author":"HY Wu","year":"2017","unstructured":"Wu HY, Peng CL, Chen PC, et al. Comparative effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers for major renal outcomes in patients with diabetes: a 15-year cohort study. PLoS One. 2017;12:1\u201316.","journal-title":"PLoS One."},{"key":"358_CR25","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1111\/j.1523-1755.2004.00620.x","volume":"65","author":"GL Bakris","year":"2004","unstructured":"Bakris GL, Weir MR, Secic M, et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004;65:1991\u20132002.","journal-title":"Kidney Int"},{"key":"358_CR26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/jhh.2010.60","volume":"25","author":"Z Zou","year":"2011","unstructured":"Zou Z, Xu FY, Wang L, et al. Antihypertensive and renoprotective effects of trandolapril\/verapamil combination: a meta-analysis of randomized controlled trials. J Hum Hypertens. 2011;25:203\u20134.","journal-title":"J Hum Hypertens"},{"key":"358_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.diabres.2005.02.019","volume":"70","author":"M P\u00e9rez-Maraver","year":"2005","unstructured":"P\u00e9rez-Maraver M, Carrera MJ, Mical\u00f3 T, et al. Renoprotective effect of diltiazem in hypertensive type 2 diabetic patients with persistent microalbuminuria despite ACE inhibitor treatment. Diabetes Res Clin Pract. 2005;70:13\u20139.","journal-title":"Diabetes Res Clin Pract"},{"key":"358_CR28","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/j.1751-7176.2008.00016.x","volume":"10","author":"RD Toto","year":"2008","unstructured":"Toto RD, Tian M, Fakouhi K, et al. Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy. J Clin Hypertens (Greenwich). 2008;10:761\u20139.","journal-title":"J Clin Hypertens (Greenwich)."},{"key":"358_CR29","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMoa042167","volume":"351","author":"P Ruggenenti","year":"2004","unstructured":"Ruggenenti P, Fassi A, Ilieva AP, Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators, et al. Preventing microalbuminiria in type 2 diabetes. N Engl J Med. 2004;351:1941\u201351.","journal-title":"N Engl J Med"},{"key":"358_CR30","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/HJH.0b013e32834069bd","volume":"29","author":"P Ruggenenti","year":"2011","unstructured":"Ruggenenti P, Fassi A, Ilieva A, et al. Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. J Hypertens. 2011;29:207\u201316.","journal-title":"J Hypertens"},{"key":"358_CR31","doi-asserted-by":"publisher","first-page":"182","DOI":"10.2174\/1573402110666140131160617","volume":"9","author":"K Homma","year":"2013","unstructured":"Homma K, Hayashi K, Yamaguchi S, et al. Renal microcirculation and calcium channel subtypes. Curr Hypertens Rev. 2013;9:182\u20136.","journal-title":"Curr Hypertens Rev"},{"key":"358_CR32","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2174\/1573402110666140131155331","volume":"9","author":"K Ando","year":"2013","unstructured":"Ando K. L-\/N-type calcium channel blockers and proteinuria. Curr Hypertens Rev. 2013;9:210\u20138.","journal-title":"Curr Hypertens Rev."},{"key":"358_CR33","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1365-2125.2012.04336.x","volume":"75","author":"C Ott","year":"2012","unstructured":"Ott C, Schneider MP, Raff U, et al. Effects of manidipine vs. amlodipine on intrarenal haemodynamics in patients with arterial hypertension. Br J Clin Pharmacol. 2012;75:129\u201335.","journal-title":"Br J Clin Pharmacol."},{"key":"358_CR34","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/hr.2016.85","volume":"40","author":"NR Robles","year":"2017","unstructured":"Robles NR, Fici F, Grassi G. Dihydropyridine calcium channel blockers and renal disease. Hypertens Res. 2017;40:21\u20138.","journal-title":"Hypertens Res."},{"key":"358_CR35","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","volume":"285","author":"LY Agodoa","year":"2001","unstructured":"Agodoa LY, Appel L, Bakris GL, et al. Effect of Ramipril versus amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285:2719\u201328.","journal-title":"JAMA"},{"key":"358_CR36","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotec-tive effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851\u201360.","journal-title":"N Engl J Med"},{"key":"358_CR37","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/hr.2009.44","volume":"32","author":"T Saruta","year":"2009","unstructured":"Saruta T, Hayashi K, Ogihara T, et al. Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J study. Hypertens Res. 2009;32:505\u201312.","journal-title":"Hypertens Res"},{"key":"358_CR38","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1161\/01.CIR.0000024416.33113.0A","volume":"106","author":"G Viberti","year":"2002","unstructured":"Viberti G. Wheeldon NM Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106:672\u20138.","journal-title":"Circulation"},{"key":"358_CR39","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1586\/14779072.6.10.1347","volume":"6","author":"FJ Mart\u00ednez Mart\u00edn","year":"2008","unstructured":"Mart\u00ednez Mart\u00edn FJ, S\u00e1iz-Satj\u00e9s M. Add-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: the AMANDHA study. Expert Rev Cardiovasc. Ther. 2008;6:1347\u201355.","journal-title":"Expert Rev Cardiovasc. Ther"},{"key":"358_CR40","first-page":"338","volume":"24","author":"NR Robles","year":"2004","unstructured":"Robles NR, Pastor L, Manj\u00f3n M, et al. Lercanidipine in diabetic patients with renal failure. Nefrologia. 2004;24:338\u201343.","journal-title":"Nefrologia"},{"key":"358_CR41","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3109\/08860220903541135","volume":"32","author":"NR Robles","year":"2010","unstructured":"Robles NR, Romero B, de Vinuesa EG, et al. Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs. Ren Fail. 2010;32:192\u20137.","journal-title":"Ren Fail"},{"issue":"Suppl 2","key":"358_CR42","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/03007995.2016.1218838","volume":"32","author":"NR Robles","year":"2016","unstructured":"Robles NR, Calvo C, Sobrino J, et al. RED LEVEL trial (REnal Disease: LErcanidipine Valuable Effect on urinary albumin Loses). Curr Med Res Opin. 2016;32(Suppl 2):29\u201334.","journal-title":"Curr Med Res Opin"},{"key":"358_CR43","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/03007995.2016.1218839","volume":"32","author":"K Tsioufis","year":"2016","unstructured":"Tsioufis K, Tsioufis C, Dimitriadis K, et al. Differential effects of lercanidipine\/enalapril versus amlodipine\/enalapril and hydrochlorothiazide\/enalapril on target organ damage and sympathetic activation in non-obese essential hypertensive subjects Curr. Med Res Opin. 2016;32:35\u201341.","journal-title":"Med Res Opin"},{"key":"358_CR44","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1161\/01.HYP.35.3.775","volume":"35","author":"M Sabbatini","year":"2000","unstructured":"Sabbatini M, Leonardi A, Testa R, et al. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension. 2000;35:775\u20139.","journal-title":"Hypertension"},{"key":"358_CR45","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1177\/1074248407300621","volume":"12","author":"T Rosenthal","year":"2007","unstructured":"Rosenthal T, Rosenmann E, Tomassoni D, et al. Effect of lercanidipine on kidney microanatomy in Cohen-Rosenthal diabetic hypertensive rats. J Cardiovasc Pharmacol Ther. 2007;12:145\u201352.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"358_CR46","first-page":"4025","volume":"22","author":"E Cerbai","year":"2018","unstructured":"Cerbai E, Mugelli A. A Lercanidipine and T-type calcium current. Eur Rev Med Pharmacol Sci. 2018;22:4025\u201331.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"358_CR47","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1097\/00004872-199816090-00017","volume":"16","author":"J De Champlain","year":"1998","unstructured":"De Champlain J, Karas M, Nguyen P, et al. Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients. J Hypertens. 1998;16:1357\u201370.","journal-title":"J Hypertens"},{"key":"358_CR48","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/hr.2010.35","volume":"33","author":"K Masuo","year":"2010","unstructured":"Masuo K, Lambert GW, Esler MD, et al. The role of sympathetic nervous activity in renal injury and end-stage renal disease. Hypertens Res. 2010;33:521\u20138.","journal-title":"Hypertens Res"},{"key":"358_CR49","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1097\/00004872-200018120-00023","volume":"18","author":"R Fogari","year":"2000","unstructured":"Fogari R, Zoppi A, Corradi L, et al. Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension. J Hypertens. 2000;18:1871\u20135.","journal-title":"J Hypertens"},{"key":"358_CR50","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1161\/01.HYP.0000058003.27729.5A","volume":"41","author":"G Grassi","year":"2003","unstructured":"Grassi G, Seravalle G, Turri X, et al. Short-versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension. Hypertension. 2003;41:558\u201362.","journal-title":"Hypertension."},{"key":"358_CR51","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.jash.2016.01.006","volume":"10","author":"G Seravalle","year":"2016","unstructured":"Seravalle G, Brambilla G, Pizzalla DP, et al. Differential effects of enalapril-felodipine versus enalapril lercanidipine combination drug treatment on sympathetic nerve traffic and metabolic profile in obesity-related hypertension. J Am Soc Hypertens. 2016;10:244\u201351.","journal-title":"J Am Soc Hypertens"},{"key":"358_CR52","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S2213-8587(18)30313-9","volume":"7","author":"J Coresh","year":"2019","unstructured":"Coresh J, Heerspink HJL, Sang Y, et al. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes Endocrinol. 2019;7:115\u201327.","journal-title":"Lancet Diabetes Endocrinol"}],"updated-by":[{"DOI":"10.1007\/s40292-020-00427-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000}}],"container-title":["High Blood Pressure & Cardiovascular Prevention"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-020-00358-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40292-020-00358-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-020-00358-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T13:53:02Z","timestamp":1612533182000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40292-020-00358-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,9]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["358"],"URL":"https:\/\/doi.org\/10.1007\/s40292-020-00358-1","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40292-020-00427-5","asserted-by":"object"}]},"ISSN":["1120-9879","1179-1985"],"issn-type":[{"value":"1120-9879","type":"print"},{"value":"1179-1985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,9]]},"assertion":[{"value":"1 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40292-020-00427-5","URL":"https:\/\/doi.org\/10.1007\/s40292-020-00427-5","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}